[1] 国家卫生健康委办公厅, 国家中医药管理局办公室. 关于印发新型冠状病毒肺炎诊疗方案（试行第七版）的通知[J/OL].[2020-04-05]. http://www.nhc.gov.cn/xcs/zhengcwj/202003/ 46c9294a7dfe4cef80dc7f5912eb1989.shtml
[2] 徐峰. 常见病的非常规药物治疗[M]. 3版. 北京: 中国医药科技出版社, 2012: 1-3.
[3] 徐峰, 黄瑾, 许铁峰. 超说明书用药[M]. 上海: 上海科技教育出版社, 2019:1-7.
[4] SWAMIDASS S J. Mining small-molecule screens to repurpose drugs[J]. Brief Bioinformatics,2011,12(4):327-335. doi:  10.1093/bib/bbr028
[5] 国家卫生健康委办公厅, 国家中医药管理局办公室. 关于印发新型冠状病毒肺炎诊疗方案(试行第六版)的通知[J/OL].[2020-04-05]. http://www.nhc.gov.cn/xcs/zhengcwj/202002/8334a8326dd94d329df351d7da8aefc2.shtml
[6] 罗敏, 胡巧织, 肖桂荣, 等. 基于FAERS的新型冠状病毒肺炎治疗用药安全信号挖掘研究: 磷酸氯喹[J]. 医药导报, http://kns.cnki.net/kcms/detail/42.1293.R.20200228.1358.004.html
[7] HOLSHUE M L, DEBOLT C, LINDQUIST S, et al. First case of 2019 novel coronavirus in the United States[J]. N Engl J Med,2020,382(10):929-936. doi:  10.1056/NEJMoa2001191
[8] 郭宗儒.由同情用药发展为Ⅲ 期临床研究的瑞德西韦[J].药学学报, http://kns.cnki.net/kcms/detail/11.2163.r.20200211.1017.002.html
[9] EINSTEIN D J. Compassion and compassionate use[J]. J Clin Oncol,2018,36(29):2969-2971. doi:  10.1200/JCO.18.00205
[10] BORYSOWSKI J, GÓRSKI A. Compassionate use of unauthorized drugs: Legal regulations and ethical challenges[J]. Eur J Intern Med,2019,65:12-16. doi:  10.1016/j.ejim.2019.04.008
[11] WEITZMAN S A, MARCY T. FDA treatment use regulations: a compassionate response[J]. AIDS Public Policy J,1987,2(2):22-32.
[12] GOLODNER L F. The US food and drug administration modernization act of 1997: impact on consumers[J]. Clin Ther,1998,20(Suppl C):C20-C25.
[13] GABAY M. 21st Century Cures Act[J]. Hosp Pharm,2017,52(4):264-265. doi:  10.1310/hpx5204-264
[14] PÉREZ MARÍN M, DECOSTERD L A, ANDRE P, et al. Compassionate use of letermovir in a 2-year-old immunocompromised child with resistant Cytomegalovirus disease[J]. J Pediatric Infect Dis Soc,2020,9(1):96-99.
[15] 宋华琳, 刘炫. 同情用药法律制度的发展与改革——以美国经验为参照探讨同情用药制度的完善[N]. 中国医药报, 2020-02-28(3).
[16] FUJIWARA Y, GOTO Y, KANDA S, et al. Efficacy and safety of osimertinib in a Japanese compassionate use program[J]. Jpn J Clin Oncol,2017,47(7):625-629. doi:  10.1093/jjco/hyx050
[17] KREFTING F, BASARA N, SCHÜTTE W, et al. Clinical experience of immunotherapy treatment: efficacy and toxicity analysis of the compassionate use program of nivolumab in patients with advanced squamous cell non-small cell lung cancer[J]. Oncol Res Treat,2019,42(5):243-255. doi:  10.1159/000499321
[18] JORIS S, PIETERS T, SIBILLE A, et al. Real life safety and effectiveness of nivolumab in older patients with non-small cell lung cancer: Results from the Belgian compassionate use program[J]. J Geriatr Oncol, 2019: S1879-S4068(19)30188-2.
[19] 国家药品监督管理局.中华人民共和国药品管理法[J/OL].[2020-04-05]. http://www.nmpa.gov.cn/WS04/CL2076/357712.html
[20] 杨悦. 实施同情用药 把控风险至关重要[N]. 健康报, 2020-02-25(5).